Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Acute Lymphoblastic Leukemia
12%
Acute Myeloid Leukemia
91%
Antineoplastic Activity
5%
Atypical Chronic Myeloid Leukemia
18%
B-Cell Chronic Lymphocytic Leukemia
6%
Biological Marker
8%
Chronic Myelogenous Leukemia
24%
Chronic Myelogenous Leukemia
12%
Chronic Neutrophilic Leukemia
22%
Clear Cell Renal Cell Carcinoma
8%
Clinical Trial
7%
Colony Stimulating Factor
8%
Cytokine
6%
Dasatinib
11%
Disease
24%
Drug Resistance
10%
Drug Response
18%
Drug Screening
7%
Drug Sensitivity
16%
Ex Vivo
29%
Fibroblast Growth Factor 2
8%
Functional Genomics
10%
Gene Expression
5%
Hematologic Malignancy
9%
In Vitro
11%
Leukemia
34%
Leukemia Cell
28%
Malignant Neoplasm
20%
Mitogen-Activated Protein Kinase
7%
Mononuclear Phagocyte
5%
Myeloproliferative Disorder
5%
Myeloproliferative Neoplasm
12%
Neoplasm
25%
Phosphotransferase
15%
Phosphotransferase Inhibitor
16%
Ponatinib
7%
Programmed Cell Death
8%
Protein Tyrosine Kinase
14%
Quizartinib
6%
Receptor
17%
Rhabdomyosarcoma
8%
Risk Stratification
6%
RNA Interference
10%
Ruxolitinib
6%
Signal Transduction
10%
T Cell
6%
Targeted Therapy
22%
Tyrosine-Kinase Inhibitor
17%
Venetoclax
30%
Xenograft
8%
Biochemistry, Genetics and Molecular Biology
Allele
9%
Antineoplastic Activity
6%
B Cell
6%
BCL6
5%
Cancer Cell
8%
Cell Transformation
6%
Colony Formation
5%
Colony-Stimulating Factor
5%
Cytokine
10%
Dasatinib
16%
Dimerization
7%
Drug Resistance
9%
Drug Response
17%
Drug Sensitivity
15%
Eicosanoid Receptor
25%
Epidermal Growth Factor Receptor
5%
Epigenetics
5%
Functional Genomics
9%
Genetics
18%
Genomics
5%
Hematopoiesis
7%
Hematopoietic Cell
5%
Imatinib
9%
Kinase
39%
Kinome
6%
Metabolomics
6%
Mitogen-Activated Protein Kinase
5%
Monocyte
6%
Mononuclear Phagocyte
5%
Mouse
8%
Myeloid
100%
Nilotinib
5%
P53
8%
Phosphotransferase
38%
Point Mutation
6%
Proteogenomics
17%
Proteomics
17%
PTPN11
5%
Receptor Tyrosine Kinase
21%
Replication Timing
5%
RNA Interference
8%
Signal Transduction
6%
Small Molecule
14%
Somatic Mutation
8%
Transcriptomics
5%
Tumor Progression
8%
Tyrosine
9%
Tyrosine Kinase
13%
Tyrosine Kinase Inhibitor
11%
Ubiquitin
5%
Keyphrases
Acquired Resistance
9%
Acute Myeloid Leukemia
64%
Acute Myeloid Leukemia Cells
5%
AP24534
5%
Apoptosis
5%
Atypical Chronic Myeloid Leukemia
6%
B Cell Receptor
5%
Bcl-2 Inhibitor
12%
BCR-ABL
10%
BCR-ABL Inhibitors
7%
Chronic Myeloid Leukemia
9%
Chronic Neutrophilic Leukemia
8%
Colony-stimulating Factor 3 Receptor
5%
CSF3R
6%
Dasatinib
11%
Drug Resistance
10%
Drug Sensitivity
8%
FLT3 mutation
5%
FMS-like Tyrosine Kinase 3 (FLT3)
15%
Functional Genomics
9%
Functional Screening
8%
Hematological Malignancies
9%
Hematopoietic Stem Cells
8%
In Cancer
10%
Inhibitor Screening
8%
Janus Kinase 2 (JAK2)
6%
Kinase Inhibitor
11%
Kinome
5%
Leukemia
17%
Leukemia Microenvironment
5%
Leukemia Patients
12%
Myeloid Cell leukemia-1 (Mcl-1)
6%
Myeloproliferative Neoplasms
9%
Ponatinib
6%
Proteogenomics
8%
RAS-MAPK Pathway
5%
Small Molecule Inhibitors
8%
Targeted Therapy
15%
Therapeutic Target
8%
Tyrosine Kinase Inhibitor
5%
Venetoclax
22%